

165

SEÑORES

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

DIVISIÓN DE NUEVAS CREACIONES

E. _____ S. _____

SUPERINTENDENCIA Y COMERCIO
Radicación: 05087348 00000003 Folios: 16
Fecha (ANO): 2005-02-13 09:25:24
Tramite: 001 PCT-PATENT 379 FASE NDCI 444 REMESA
Dependencia: 2920 DIVISION DE NUEVAS CREACIONES

Ref.: Expediente N°. 05-087.348

Solicitud de Patente de Invención Titulada: "METODOS PARA PREVENIR LA
GLUCONOILACION DE PROTEINAS"

Solicitante: SMITHKLINE BEECHAM CORPORATION

RESPUESTA AL OFICIO N°. 9487 NOTIFICADO
POR FIJACION EN LISTA No. 407, DE FECHA 14 DE OCTUBRE DE 2005,
(EXAMEN DE FORMA)

CARLOS R. OLARTE, mayor de edad y vecino de Bogotá, identificado tal como aparece al pie de mi firma, en mi carácter de apoderado de la sociedad en referencia, me permito dar respuesta al auto proferido por ese Despacho, dentro del término de prórroga solicitado en mi memorial de fecha 1 de diciembre de 2005, en los siguientes términos:

1. En respuesta a la primera observación del Examinador, me permito remitir a su atención el Reporte Preliminar de Patentabilidad (Capítulo II del PCT), emitido por la oficina de Examen, Preliminar Internacional, el cual, valga aclarar, no contiene anexos.

bb

2. En respuesta a la segunda observación del Examinador, me permito aportar junto al presente memorial, el documento de cesión debidamente legalizado, junto con su correspondiente traducción, según lo previsto en el Art. 26- k de la Decisión 486.

Atentamente,



CARLOS R. OLARTE
C.C. No. 79.782.747 de Bogotá
T.P. 74.295

Anexo: Reporte Preliminar Internacional de Patentabilidad.
 Documento de Cesión

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:
ANDREA V. LOCKENOUR
GLAXOSMITHKLINE
CORPORATE INTELLECTUAL PROPERTY, UW2220
709 SWEDLAND ROAD, PO BOX 1539
KING OF PRUSSIA, PA 19406-0939

PCT

NOTIFICATION OF TRANSMITTAL OF
INTERNATIONAL PRELIMINARY
REPORT ON PATENTABILITY
(Chapter II of the Patent Cooperation Treaty)

(PCT Rule 71.1)

Date of mailing
(day/month/year)

01 FEB 2006

Applicant's or agent's file reference

PU60116

IMPORTANT NOTIFICATION

International application No.

PCT/US04/06507

International filing date (day/month/year)

04 March 2004 (04.03.2004)

Priority date (day/month/year)

04 March 2003 (04.03.2003)

Applicant

SMITHKLINE BEECHAM CORPORATION

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the *PCT Applicant's Guide*.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed invention is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the IPEA/ US

Mail Stop PCT, Attn: IPEA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (571) 273-3201

Authorized officer

Christian L. Frouda

Telephone No. (571) 272-1600

Form PCT/IPEA/416 (January 2004) 2006 FEB - 3 P 2:52

RECEIVED
GLAXOSMITHKLINE

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

168
168

Applicant's or agent's file reference PU60116		FOR FURTHER ACTION		See Form PCT/IPEA/416
International application No. PCT/US04/06507		International filing date (day/month/year) 04 March 2004 (04.03.2004)	Priority date (day/month/year) 04 March 2003 (04.03.2003)	
International Patent Classification (IPC) or national classification and IPC IPC(7): C12N 9/14, 9/16, 1/20, 15/00; C07H 21/04 and US Cl.: 435/195, 196, 252.3, 320.1; 536/23.2				
Applicant SMITHKLINE BEECHAM CORPORATION				
1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 2. This REPORT consists of a total of <u>7</u> sheets, including this cover sheet. 3. This report is also accompanied by ANNEXES, comprising: a. ☐ (sent to the applicant and to the International Bureau) a total of _____ sheets, as follows: ☐ sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions). ☐ sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box. b. ☐ (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) _____, containing a sequence listing and/or tables related thereto, in electronic form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).				
4. This report contains indications relating to the following items: ☒ Box No. I Basis of the report ☐ Box No. II Priority ☒ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability ☐ Box No. IV Lack of unity of invention ☒ Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement ☐ Box No. VI Certain documents cited ☐ Box No. VII Certain defects in the international application ☐ Box No. VIII Certain observations on the international application				
Date of submission of the demand 15 September 2004 (15.09.2004)			Date of completion of this report 21 January 2006 (21.01.2006)	
Name and mailing address of the IPEA/ US Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201			Authorized officer Christian L. Fronda <i>F. Roberts for</i> Telephone No. (571) 272-1600	

Form PCT/IPEA/409 (cover sheet)(April 2005)

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/US04/06507

169 109

Box No. 1 Basis of the report

1. With regard to the language, this report is based on:

- ☒ the international application in the language in which it was filed.
- ☐ a translation of the international application into English, which is the language of a translation furnished for the purposes of:
- ☐ international search (under Rules 12.3 and 23.1(b))
- ☐ publication of the international application (under Rule 12.4(a))
- ☐ international preliminary examination (under Rules 55.2(a) and/or 55.3(a))

2. With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):

- ☒ the international application as originally filed/furnished
- ☒ the description:
- pages 1-38 as originally filed/furnished
- pages* NONE received by this Authority on _____
- pages* NONE received by this Authority on _____
- ☒ the claims:
- pages 39-43 as originally filed/furnished
- pages* NONE as amended (together with any statement) under Article 19
- pages* NONE received by this Authority on _____
- pages* NONE received by this Authority on _____
- ☒ the drawings:
- pages 1-14 as originally filed/furnished
- pages* NONE received by this Authority on _____
- pages* NONE received by this Authority on _____

☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.

3. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheets/figs _____
- ☐ the sequence listing (specify): _____
- ☐ any table(s) related to the sequence listing (specify): _____

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheets/figs _____
- ☐ the sequence listing (specify): _____
- ☐ any table(s) related to the sequence listing (specify): _____

* If item 4 applies, some or all of those sheets may be marked "superseded."

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/US04/06507

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application
- ☒ claims Nos. 19-25, 31-33 and 35-42

because:

- ☐ the said international application, or the said claim Nos. _____ relate to the following subject matter which does not require an international preliminary examination (*specify*):
- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _____ are so unclear that no meaningful opinion could be formed (*specify*):
- ☒ the claims, or said claims Nos. 19-25, 31-33 and 35-42 are so inadequately supported by the description that no meaningful opinion could be formed (*specify*):

The claims recite specific SEQ ID NOs. However, a computer readable form of the sequence listing has not been provided. Thus, a meaningful search of the specific SEQ ID NOs cannot be carried out.

- ☐ no international search report has been established for said claims Nos. _____
- ☐ a meaningful opinion could not be formed without the sequence listing; the applicant did not, within the prescribed time limit:
- ☐ furnish a sequence listing on paper complying with the standard provided for in Annex C of the Administrative Instructions, and such listing was not available to the International Preliminary Examining Authority in a form and manner acceptable to it.
- ☐ furnish a sequence listing in electronic form complying with the standard provided for in Annex C of the Administrative Instructions, and such listing was not available to the International Preliminary Examining Authority in a form and manner acceptable to it.
- ☐ pay the required late furnishing fee for the furnishing of a sequence listing in response to an invitation under Rules 13ter.1(a) or (b) and 13ter.2.
- ☐ a meaningful opinion could not be formed without the tables related to the sequence listings; the applicant did not, within the prescribed time limit, furnish such tables in electronic form complying with the technical requirements provided for in Annex C-bis of the Administrative Instructions, and such tables were not available to the International Preliminary Examining Authority in a form and manner acceptable to it.
- ☐ the tables related to the nucleotide and/or amino acid sequence listing, if in electronic form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.
- ☐ See Supplemental Box for further details

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/US04/06507

171

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims <u>1-18, 26-30, 34 and 43-49</u>	YES
	Claims <u>NONE</u>	NO
Inventive Step (IS)	Claims <u>NONE</u>	YES
	Claims <u>1-18, 26-30, 34, 43-59</u>	NO
Industrial Applicability (IA)	Claims <u>1-18, 26-30, 34, 43-59</u>	YES
	Claims <u>NONE</u>	NO

2. Citations and Explanations (Rule 70.7)
Please See Continuation Sheet

172

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of:

V. 2. Citations and Explanations:

Claims 28-30, 34 lack an inventive step under PCT Article 33(3) as being obvious over Guan et al. (US Patent 5,643,758) in view of Kupor et al. *J Bacteriol.* 1969 Dec;100(3):1296-301.

Guan et al. (US Patent 5,643,758) teach expression vectors, prokaryotic and eukaryotic host cells including *E. coli* host cells, and methods for making, expressing, isolating, and purifying any protein fused to the *E. coli* maltose binding protein (MBP) using the said expression vectors, prokaryotic and eukaryotic host cells; and that these methods and products are useful for purifying virtually any hybrid polypeptide molecule employing recombinant techniques (see entire publication of US Patent 5,643,758).

Kupor et al. (*J Bacteriol.* 1969 Dec;100(3):1296-301) teach the *Escherichia coli* K-12 *pgl* gene (see entire publication). Zimenkov et al. (*FEMS Microbiol Lett.* 2005 Mar 15;244(2):275-80) provide evidence that the *Escherichia coli* K-12 *yhjE* gene is the *pgl* gene that encodes 6-phosphogluconolactonase (see entire publication).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to use the *E. coli* host cell of Guan et al. such that the *E. coli* host cell is transformed with the *pgl* gene encoding 6-phosphogluconolactonase taught by Kupor et al. One of ordinary skill in the art would be motivated to do this for the purpose of having *E. coli* host cells transformed with *pgl* gene that can be used in expression methods for producing and isolating the *E. coli* K-12 6-phosphogluconolactonase.

Claims 1-9, 12-18, 26, 27 lack an inventive step under PCT Article 33(3) as being obvious over the prior art as applied in the immediately preceding paragraph and further in view of Nanba et al. (*J Biocatal Bioeng.* 1999;87(2):149-54).

Nanba et al. teach a method comprising culturing *E. coli* host cells in medium comprising nitrogen source, tryptone, and yeast extract for the production of N-carbamyl-D-amino acid amidohydrolase (see entire publication).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the method of

193

Supplemental Box

Namba et al. such that the modified *E. coli* host cell of Guan et al. stated above is used in the method. One of ordinary skill in the art would be motivated to do this for the purposes of producing the *E. coli* K-12 6-phosphogluconolactonase in large amounts which in turn would prevent gluconoylation of any polypeptide desired to be expressed in the modified *E. coli* host cell.

Claims 10, 11 lack an inventive step under PCT Article 33(3) as being obvious over the prior art as applied to claims 28-30, 34 and further in view of Madurawe et al. (Biotechnol Prog. 2000 Jul-Aug; 16(4):571-6)

Madurawe et al. teach a method comprising culturing *E. coli* host cells in medium comprising super broth for the production of a lipoprotein antigen against Lyme disease with improved yield (see entire publication).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to further modify the modified method of Madurawe et al. such that super broth is used in culturing. One of ordinary skill in the art would be motivated to do this for the purposes of producing the *E. coli* K-12 6-phosphogluconolactonase with improved yields which in turn would prevent gluconoylation of any polypeptide desired to be expressed in the modified *E. coli* host cell.

Claims 43-46 lack an inventive step under PCT Article 33(3) as being obvious over the prior art as applied to claims 1-9, 12-18, 26, 27 and further in view of Kim et al. (Acta Crystallogr D Biol Crystallogr. 2001 May; 57(Pt 5):759-62. Epub 2001 Apr 24).

Kim et al. teach that alpha-N-6-gluconoylation of the N-terminal His tag interferes with crystallization of the wild-type and mutant SH3 domains of chicken src tyrosine kinase (see entire publication).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to use the modified method of Madurawe et al. such that a desired polypeptide is expressed for improved crystal formation. One of ordinary skill in the art would be motivated to do this since Kim et al. teach that alpha-N-6-gluconoylation of proteins interferes with crystallization of proteins, where the modified *E. coli* host cell of Guan et al. prevents gluconoylation of proteins.

Claims 47-55 lack an inventive step under PCT Article 33(3) as being obvious over the prior art as applied to claims 1-9, 12-18, 26, 27 and further in view of Gracie et al. (J Leukoc Biol. 2003 Feb; 73(2):213-24).

Gracie et al. teach the polynucleotide encoding interleukin IL-18 (see entire publication).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to further modify the modified method of Madurawe et al. such that the modified *E. coli* host cell of Guan et al. is transformed with the polynucleotide encoding interleukin IL-18 taught by Gracie et al. One of ordinary skill in the art would be motivated to do this for the purpose of expressing human interleukin IL-18 which lacks N-6-gluconoylation.

Claims 56-59 lack an inventive step under PCT Article 33(3) as being obvious over Studier et al. (J Mol Biol. 1986 May 5; 189(1):113-30) in view of Katsura (J Mol Biol. 1989 Jan 20; 205(2):397-405).

Studier et al. teach *E. coli* host cells infected with a lambda phage derivative that carries the gene for T7 RNA polymerase (see entire publication).

Katsura teach that amino acid substitutions in the major capsid protein (gene E product) of lambda phage causes a defect in DNA packaging (see entire publication).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the lambda phage derivative taught by Studier et al. such that the gene E is deleted or disrupted thereby resulting in modified *E. coli* host cells having a T7 RNA polymerase gene and lambda phage which is defective in DNA packaging. One of ordinary skill in the art would be motivated to do this for the purpose of expressing recombinant proteins in the modified *E. coli* host cells which does not produce any lambda phage.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/US04/06507

174
174

Supplemental Box

Claims 1-18, 26-30, 34, 43-59 meet the criteria set out in PCT Article 33(4), and thus has industrial applicability because the subject matter claimed can be made or used in industry.

PATENT COOPERATION TREATY

PCT

NOTE OF INFORMAL COMMUNICATION WITH THE APPLICANT

(PCT Rule 66.6)

International application No. PCT/US04/06507	Applicant's or agent's file reference PU60116	Date of informal communication (day/month/year) 20 January 2006 (20.01.2006)
Applicant SMITHKLINE BEECHAM CORPORATION		

Communication ☒ by telephone ☐ personal	Participants ☒ Applicant: SMITHKLINE BEECHAM CORPORATION ☒ Agent: Andrea B. Lockenour ☒ Examiner(s): Christian L. Fronda	☒ Identity checked ☐ authorization checked ☐ personally known
---	--	---

Summary of communication:

Upon request by the applicants' representative, Andrea V. Lockenour, it was agreed to proceed to the 409 IPER in order to meet the applicants' administrative deadlines for the instant application.

☐ An extension of time limit is granted (Form PCT/IPEA/427).

☒ A copy of this note is being sent to the applicant with Form PCT/IPEA/428.

PCT/IPEA/416 & 409.

Name and mailing address of the IPEA/US Mail Stop PCT, Attn: IPEA/ US Commissioner for Patents P.O. Box 1430 Alexandria, Virginia 22313-1430 Facsimile No. (571) 273-3201	Authorized officer Christian L. Fronda Telephone No. (571) 272-1600
--	---

Form PCT/IPEA/428 (July 1992)

175
#425

176
176

Nosotros, ALAN R. GARDNER, THOMAS D. SWEITZER, ALEXANDER H. TAYLOR Y PRAMATHESH S. PATEL de 709 Swedeland Road, Reino de Prussia, Pensilvania 19406, Estados Unidos de América,

Por medio de la presente cedemos a

SMITHKLINE BEECHAM CORPORATION

Una compañía organizada bajo las leyes de La Comunidad de Naciones de Pennsylvania, uno de los Estados Unidos de América,

domiciliada en

One Franklin Plaza Philadelphia, Pennsylvania 19101,
Estados Unidos de América

(en adelante el "Cesionario"), todos mis (nuestros) derechos, título e interés sobre mi(nuestra) invención tal como describe en:

METODOS PARA PREVENIR LA GLUCONOILACION DE PROTEINAS.

No. Serial: 60/451,686

Presentada el 4 de marzo de 2003

en lo que concierne a la República de Colombia.

Lugar y Fecha: Reino de Prussia, Pennsylvania, U.S.A. el 13 de febrero de 2004.

(Fdo) ALAN R. GARDNER

(Fdo) THOMAS D. SWEITZER

(Fdo) ALEXANDER H. TAYLOR

(Fdo) PRAMATHESH S. PATEL

Jurado y suscrito ante mí, el día 13 de febrero de 2004

(Fdo) IRENE M. MULLIGAN Notario Público

Sello Notarial,

de Irene M. Mulligan

Notario Público

Upper Merion. Twp., Condado de Montgomery

Mi comisión vence el 20 de octubre de 2005

Miembro de la asociación de notarias de Pensilvania

~~10-129~~

APOSTILLA

(Convención de la Haya del 5 de Octubre de 1961)

1. País: Estados unidos de América
El presente documento público
2. Ha sido firmado por: **IRENE M MULLIGAN**
3. Actuando en su calidad de Notario Público
4. Aparece el sello IRENE M MULLIGAN, NOTARIO PUBLICO,
CONDADO DE MONTGOMERY, COMUNIDAD DE NACIONES DE
PENNSYLVANIA.
Se certifico
5. En Harrisburg, Pennsilvania
6. El 11 de marzo de 2004
7. Por Pedro A. Cortés, Secretario de la Comunidad de
Naciones de Pennsilvania.
8. Bajo el Número **200408143**
9. Lleva el Sello del Secretario de la Comunidad de
Naciones de Pennsilvania.
10. Firmado por Pedro A. Cortés.


15129

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country : United States Of America
2. This public document has been signed by IRENE M MULLIGAN
acting in the capacity of NOTARY PUBLIC
4. bears the seal/stamp IRENE M MULLIGAN, NOTARY PUBLIC, MONTGOMERY COUNTY, COMMONWEALTH OF PENNSYLVANIA
5. at Harrisburg, Pennsylvania
6. The 11th day of March, 2004
7. by Pedro A. Cortés, Secretary of the Commonwealth of Pennsylvania
8. No : 200408143
9. Seal/Stamp
10. Signature

Certified



Pedro A. Cortés

Pedro A. Cortés

16100

OLARTERAISBECK

Carlos R. Olarte
J. Ian Raisbeck
Ana Maria Frieri

Olarte Raisbeck & Frieri, Ltda.
Legal & Professional Services

Zayde Chamin

World Trade Center - Torre C
Calle 100 No. 8A-55 Piso 10
Bogota, Colombia
Telephone: +57-1 638-6200
Fax: +57-1 638-6201

www.olarteraisbeck.com

ASSIGNMENT

CESION

I/ We, **ALAN R. GARDNER, THOMAS D. SWEITZER, ALEXANDER H. TAYLOR, and PRAMATHESH S. PATEL** of 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States of America, by means of this document assign(s) to **SMITHKLINE BEECHAM CORPORATION**, a corporation organized under the laws of the Commonwealth of Pennsylvania, one of the United States of America, domiciled in One Franklin Plaza Philadelphia, Pennsylvania 19101 United States of America (hereinafter referred to as the "ASSIGNEE"), all my(our) rights, title and interest in and to my(our) invention for a new and useful improvement entitled and as fully set forth and described in: **"METHODS FOR PREVENTING GLYCONOYLATION OF PROTEINS"** Serial No. 60/451,686 Filed on 04 March 2003 so far as the Republic of Colombia is concerned.

por medio de la presente cedo (cedemos) a **SMITHKLINE BEECHAM CORPORATION**, una organizada bajo las leyes de domiciliada en One Franklin Plaza Philadelphia, Pennsylvania 19101 United States of America (de ahora en adelante el "CESIONARIO"), todos mis(nuestros) derechos, título e interés sobre mi(nuestra) invención tal como describe en:

en lo que concierne a la República de Colombia.

Place and date: King of Prussia, Pennsylvania, U.S.A. on February 13, 2004.

Lugar y fecha:



ALAN R. GARDNER


THOMAS D. SWEITZER


ALEXANDER H. TAYLOR


PRAMATHESH S. PATEL

Sworn to and subscribed before me this 13th day of February, 2004.


Notary Public

Notarial Seal
Irene M. Mulligan, Notary Public
Upper Merion Twp., Montgomery County
My Commission Expires Oct. 20, 2006
Member, Pennsylvania Association of Notaries

181

REPUBLICA DE COLOMBIA
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Folio 181

2020
Bogotá D.C.,


Doctor(a)
OLARTE GARCIA CARLOS REINALDO
Apoderado(a) y/o Representante de
SMITHKLINE BEECHAM CORPORATION

REFERENCIA	Radicación No.	05 87348
	Solicitud internacional	US2004/006507
	Fecha inicio fase nacional	04/10/2005
	Trámite	11
	Evento	379
	Actuación	416
	Oficio No.	2335
	Folios	1

Teniendo en cuenta que la solicitud de privilegio de patente que se tramita bajo el expediente indicado en la referencia, reúne los requisitos de forma establecidos en la Decisión 486 de la Comisión de la Comunidad Andina, el Tratado de Cooperación en Materia de Patentes (PCT), el Reglamento y la Circular Única de la Superintendencia de Industria y Comercio, se envía el extracto de la solicitud a la Oficina de Comunicaciones para efecto de su publicación en la Gaceta de Propiedad Industrial.

Cúmplase
Dado en Bogotá DC,

26 DIC. 2005


ALIX CARMENZA CESPEDES DE VERGEL
Jefe de la división de Nuevas Creaciones

adpa10